Introduction
The myc family of cellular proto-oncogenes encode for nuclear phosphoproteins which are believed to be involved in the establishment of numerous types of human malignancy (Zimmerman and Alt, 1990; Field and Spandidos, 1990; Spencer and Groudine, 1991) . Enforced expression of the most studied family member, c-myc, can result in cell-cycle progression and inhibition of dierentiation in many cell lineages (Ingvarsson, 1990; Luscher and Eisenman, 1990; Evan and Littlewood, 1993) . Furthermore, when c-myc is expressed in conjunction with a second oncogene, e.g. c-Ha-ras, it has been shown to induce cellular transformation (Land et al., 1983) and, somewhat paradoxically, when expressed in situations of growth factor deprivation or cell-cycle restraint, to bring about programmed cell death (apoptosis) (Askew et al., 1991; Evan et al., 1992) .
The mechanisms by which c-Myc brings about cellcycle progression, cellular transformation and apoptosis have now been partially elucidated and appear to involve some common factors. Firstly, it has been shown that in order to invoke these eects, c-Myc must form a heterodimeric complex with a smaller unrelated protein, termed Max (Amati et al., 1993a,b) . As it is considered that c-Myc cannot bind DNA alone, it is perceived that it is in conjunction with Max that c-Myc binds to the previously described E-box motif (CACGTG) and regulates the expression of its target genes (Blackwood et al., 1992) . In this regard, it is one of these target genes, ornithine decarboxylase (ODC), that is the second common factor involved in the three phenotypes described above. It has been shown that, in general, the levels of both c-Myc (Kelly and Siebenlist, 1986) and ODC (Pegg, 1986 ) are elevated during cellcycle progression and are essential for entry into S phase (Bowlin et al., 1986; Heikkila et al., 1987) . In addition, through the use of an irreversible inhibitor of ODC enzymic activity, a-di¯uoromethylornithine (DFMO), Auvinen et al. (1992) showed that the transformation of cells by tyrosine kinase oncogenes, which is known to be dependent on c-Myc (Sawyers et al., 1992) , is also dependent on the activity of ODC. This inhibitor has also been used to show that the Myc-induced apoptosis that occurs in haemopoietic cells upon growth factor withdrawal is also abrogated by the inhibition of ODC (Peckham and Cleveland, 1994) .
The ®nding that these factors are common to the mechanisms by which c-Myc causes cell-cycle progression, cellular transformation and apoptosis is very encouraging. However, as it has not been shown that these factors are involved in the ability of c-Myc to block dierentiation, the way in which the protein controls this process remains less well de®ned. One school of thought has grown to consider that c-Myc blocks dierentiation solely as a result of its ability to direct continued cell-cycle progression. This postulate is based on the fact that many cell lineages must undergo growth arrest in order to dierentiate terminally. However, it is equally possible that the ability of c-Myc to block dierentiation can occur via a novel mechanism that is dissociated, at least in part, from its ability to cause cell-cycle progression. While many workers have shown that the down-regulation of c-myc expression is an event accompanying the induced dierentiation of many in vitro systems (Lachman and Skoultchi, 1984; Finkelstein and Weinberg, 1988; Mitchell et al., 1992) , attributing any eect or activity of c-Myc speci®cally to the dierentiation process has been dicult due to the concomitant growth arrest that these cells undergo following induction of the dierentiation programme. In order to overcome this problem we have analysed variants of the human leukaemic cell line, U937 (Harris and Ralph, 1985) , which dier in their response to treatment with the dierentiation inducers. One of these variants, U937d7, diers from its parental line, U937d+, in that while it still undergoes rapid growth arrest following treatment with phorbol ester, it does not simultaneously dierentiate into monocytes/macrophages. Our analysis of these two cell lines surprisingly showed that they had marked dierences in the expression pro®le of c-myc that occurred following treatment with the phorbol ester. On the basis of our ®ndings we present here our hypothesis and supporting data that indicate that c-Myc can block dierentiation by a mechanism distinct from that involved in cellcycle progresssion.
Results

Loss of Myc protein expression is not obligatory for growth arrest in myeloid leukaemic cells
In order to investigate the mechanism by which c-Myc can abrogate the ability of myeloid cells to differentiate, we analysed the expression of c-myc mRNA and protein in a number of variants of leukaemic cell lines which dier in the way in which they respond to treatment with inducers of terminal dierentiation. One of these lines, which we have termed U937d7, is a variant of the human myeloid cell line U937 (described here as U937d+) (Harris and Ralph, 1985) . Analysis of this line revealed that it diered from its`wild-type' counterpart (U937d+) in that it did not undergo a programme of dierentiation to monocytes/macrophages following treatment with the phorbol ester, TPA. Morphological analysis (Figure 1 ) clearly shows U937d7 cells to be unlike U937d+ cells in that, following treatment with TPA, they do not form aggregates and adhere to the plastic of the tissue culture dish and in fact look exactly like cultures that have not been treated with the dierentiation inducer. Furthermore, when analysed histochemically it was found that U937d7 cells were again dierent from U937d+ cells in that treatment with TPA did not induce the activity of the terminal dierentiation marker, non-speci®c esterase (NSE) (data not shown). However, in spite of these ®ndings, we found that U937d7 cells did respond to the dierentiation inducer by undergoing a growth arrest which occurred in a similar manner, if not even more quickly, to that seen in U937d+ cells (Figure 2) . Moreover, the growth arrest of U937d7 cells was found to be stable and¯ow cytometry pro®les of cells analysed intermittently up to a period of 3 weeks were found to be identical to the pro®le observed following 5 days of treatment with TPA (data not shown). In addition, after treating the cells for 7 days with TPA, we found that neither removal of the phorbol ester and/or addition of fresh medium and serum were able to send the cells back into the cell cycle (data not shown).
As loss of c-Myc protein has been shown to be a characteristic change that accompanies the induced dierentiation of`wild-type' U937 cells (Larsson et al., 1994) , we measured the abundances of c-Myc in U937d7 and U937d+ cells. While we also found that c-Myc was decreased in U937d+ cells, following treatment with TPA for 3 days (Figure 3) , the levels of c-Myc in U937d7 cells were maintained at the levels observed in untreated cells (Figure 3) . Furthermore, analyses beyond day 7 showed that c-Myc protein was maintained at these levels for up to 3 weeks following initiation of treatment with TPA (data not shown). This ®nding, in conjunction with the fact that these cells are growth arrested (Figure 2) , indicates that the down-regulation of the levels of c-Myc protein is not a requirement for these cells to withdraw from the cell cycle.
The relative abundances of c-Myc and its antagonists are the same in TPA-treated U937d7cells as in untreated cells
It has been shown previously that the levels of the mRNAs for Mad1 and Mxi1 are both elevated following TPA-treatment of U937 cells (Larsson et al., 1994; Ayer and Eisenman, 1993) . Therefore, if the levels of these cMyc-antagonists are also elevated following TPA treatment of U937d7 cells, then although these cells maintain high levels of c-Myc expression, it may be that it does not have functional capacity due to high levels of its antagonists, Mad1 and/or Mxi1. To investigate this possibility, we analysed the levels of the mRNAs for Mad1 and Mxi1 in U937d+ and U937d7 cells following treatment with TPA. This revealed that although in agreement with previous studies (Larsson et al., 1994; Ayer and Eisenman, 1993 ) the abundance of mxi1 mRNA was moderately increased following TPA treatment of U937d+ cells, the levels of this message in U937d7 cells (apart from a minor, transient increase at 4 h) were unaected by this treatment (Figure 4 ). In addition, analysis of the levels of mad1 mRNA in U937d7 cells revealed that, unlike in U937d+ cells which induced and maintained high levels of mad1 mRNA, the levels were only transiently increased at the 2 h time point and were then down-regulated again to levels that were at least as low as in uninduced cells (Figure 4 ). Providing these ®ndings can be translated into changes in protein abundance, these observations indicate that the balance of c-Myc and its antagonists is the same in TPA-treated U937d7 cells as it is in untreated cells.
Expression of ODC is down-regulated in U937d7cells following treatment with TPA, despite continued c-Myc expression
It has been shown that the activity of the protein product of the Myc target gene ODC is essential for cell-cycle progression (Pegg, 1986) . Furthermore, it has also been reported that activation of c-Myc alone, at least in ®broblasts, is sucient to induce the expression of ODC (Wagner et al., 1993) . However, while we have shown here that the relative levels of c-Myc and its antagonists are the same in TPA-treated U937d7 cells (despite a transient change in the levels of mad1 mRNA) as they are in untreated U937d7 cells, this does not necessarily mean that these cells also maintain expression of ODC. We therefore analysed the levels of ODC mRNA following incubation with TPA for a period of 7 days, and found that treatment with the phorbol ester decreased the levels of ODC in both U937d+ and U937d7 cells ( Figure 5 ). Moreover, the levels of ODC mRNA were decreased more rapidly in U937d7 than in U937d+ cells. Since the protein is Equal quantities of protein from each time point were resolved through polyacrylamide gels, blotted and assessed for Myc protein using an antiserum which had been raised against the full-length human c-Myc protein. The more slowly migrating second band that is seen in U937d7 proteins following treatment with TPA for 1 day was not consistently seen during these studies and we therefore believe it is artefactual. However, the pro®les of c-Myc protein were consistently reproducible extremely unstable (t 1/2 =15 min) (Pegg, 1986; Hayashi and Murakami, 1995) , it can be predicted that loss of ODC activity will occur soon after the loss of its mRNA. With this in mind, these ®ndings provide a possible reason why, in spite of continued c-Myc expression, U937d7 cells withdraw from the cell-cycle following treatment with TPA. However, the mechanism by which the expression of ODC is down-regulated remains undetermined.
The block to dierentiation in U937d7cells can be released by antisense oligonucleotides directed against c-myc mRNA
On the basis of our ®ndings (Figures 1 ± 3) we hypothesised that the block to dierentiation of U937d7 cells may be as a result of the continued expression of c-myc in these cells and yet, however, dissociated from the ability of c-Myc to direct cell-cycle progression. To answer this question, we downregulated the levels of c-Myc protein in TPA-treated U937d7 cells with antisense oligonucleotides directed against the c-myc mRNA. One oligonucleotide, which we found to be particularly eective, had previously been used to reduce the levels of c-Myc protein, and subsequently induce growth arrest (Wickstrom et al., 1989) and dierentiation (Bacon and Wickstrom, 1991) , in the human promyelocytic leukaemia cell line, HL60. When we incubated U937d7 cells for 5 days with both this oligonucleotide and TPA we observed a marked decrease in the levels of c-Myc protein when compared to that observed in cells treated for the same period with TPA alone ( Figure  6 ). Furthermore, this down-regulation was not observed when the cells were incubated with TPA and either a complementary c-myc sense oligonucleotide or a non-speci®c degenerate oligonucleotide ( Figure 6 ). We also assessed the dierentiation status of the cells following treatment with the oligonucleotides. In agreement with our hypothesis, we found that treatment with c-myc antisense oligonucleotide, but not with the complementary sense or a degenerate oligonucleotide, resulted in morphological changes in the cells which were characteristic of the appearance of U937d+ cells following their dierentiation induced by TPA (Figure 7) . We subsequently assessed whether these morphological changes resulted from the differentiation of U937d7 cells, by histochemical analysis of the activity of the terminal dierentiation marker, NSE. We found that treatment with the antisense oligonucleotide resulted in approximately 50% of the cells having high levels of NSE activity. In contrast, only 2 ± 3% of the cells treated with the sense or degenerate oligonucleotide showed induction of this marker (data not shown).
It has been proposed that the eects of antisense oligonucleotides containing a quartet of dG residues (including the c-myc antisense oligonucleotide used in these experiments) may be by a mechanism that does not involve sequence-speci®c hybridisation to the target 0hr  1hr  2hr  4hr  8hr  16hr  24hr  48hr  72hr  120hr  168hr  0hr  1hr  2hr  4hr  8hr  16hr  24hr  48hr  72hr  120hr  168hr Hours following TPA treatment
Hours following TPA treatment Figure 4 Analysis of the changes in the relative levels of max, mad1 and mxi1 mRNAs following TPA treatment of U937d+ and U937d7 cells. Both U937d+ and U937d7 cells were treated with TPA at a ®nal concentration of 1.6610 77 M. The Northern blots were initially hybridised with a cDNA probe for mad1 mRNA, then stripped and hybridised with a probe for mxi1 mRNA, stripped again and hybridised with a probe for max mRNA, and then ®nally stripped again and as an assessment of loading rehybridised with a probe for b 2 -microglobulin mRNA. Sections of the ®gure relating to each probing are labelled accordingly gene mRNA (Burgess et al., 1995) . In order to eliminate this possibility, these studies were also repeated with the second random/degenerate oligonucleotide (see Materials and methods), which contained a dG quartet. The results obtained with this oligonucleotide (data not shown) were identical to those seen with the c-myc sense and the degenerate/ random oligonucleotides used for the experiments in Figure 7 . Therefore, it is unlikely that the eects we observed of the c-myc antisense oligonucleotide on U937d7 cells arose because of the presence of a dG quartet in the oligonucleotide. Also, all the oligonucleotides used (c-myc antisense, sense and degenerate) were phosphorothiolated so the eect seen with the c-myc antisense oligonucleotides on U937d7 cells was not the same as that on human glioma cells (Chavany 
Hours following TPA treatment Figure 5 Northern blot analysis of RNAs isolated, at the times indicated, from U937d+ and U937d7 cells following treatment with TPA at a ®nal concentration of 1.6610 77 M. The blots were initially hybridised with a cDNA probe for ODC mRNA, subsequently stripped and then as an assessment of loading were re-hybridised with a probe for b 2 -microglobulin mRNA. Sections of the ®gure relating to each probing are labelled accordingly
Cont
Myc AS Myc s Degen. oligö Myc Figure 6 Western blot analysis showing the eects of treating U937d7 cells with antisense oligonucleotides directed against the c-myc mRNA. In addition to treatment with TPA to a ®nal concentration of 1.6610 77 M, the cells were also subjected to daily addition of oligonucleotide at a concentration of 20 mM, for a period of 5 days. Control cells (Cont.) were treated with TPA alone for the same period of time. Myc AS, antisense oligonucleotide directed against the 5' of c-myc mRNA. Myc S, complementary sense oligonucleotide. Degen. oligo, degenerate oligonucleotide. A second independent experiment gave identical results
U937d-+TPA
U937d-+TPA + myc sense oligo U937d-+TPA + myc anti-sense oligo Figure 7 Morphological appearance of U937d7 cells that have been treated with anti-sense oligonucleotides directed against the c-myc mRNA. Cells were treated for 5 days with TPA at a ®nal concentration of 1.6610 77 M and, where indicated, for 5 days with a daily addition of 20 mM oligonucleotide. These eects were reproducibly seen in three independent experiments et al., 1995). Together, therefore, these ®ndings show that the block to dierentiation in U937d7 cells involves the continued expression of c-Myc protein (Figure 3 ), but does not involve the protein product of the Myc target gene, ODC ( Figure 5 ).
Discussion
It was the aim of this study to gain insight into the mechanism by which c-Myc can block the differentiation of myeloid cells. It had previously been shown that terminal dierentiation in a number of cell lineages, including myeloid, occurs simultaneously with a withdrawal from the cell cycle and downregulation of the levels of c-Myc (Ingvarsson, 1990; Zimmerman and Alt, 1990) . It was considered that cMyc aects the dierentiation process in one of two ways. Firstly, constitutive expression of c-Myc could be interfering with the dierentiation process by a mechanism distinct from its involvement in cell-cycle progression. Alternatively, it could be that by sustaining cell-cycle progression, c-Myc could indirectly aect this process, since in general proliferation and terminal dierentiation are mutually exclusive. In order to address this question, we utilised a variant of the human leukaemic cell line, U937. This line is unlike its`wild-type' counterpart in that, although it responds to treatment with the dierentiation inducer, TPA, by undergoing a rapid and irreversible growth arrest, it does not concomitantly undergo a programme of dierentiation.
Our ®nding that the levels of c-Myc protein in U937d7 cells are unaected by treatment with TPA also diered from that during the induced differentiation of the parental line, U937d+. In addition, continued expression of c-Myc in growth arrested cells is in contrast to studies in ®broblasts which indicated that c-Myc alone is sucient to direct cellcycle progression (Eilers et al., 1990) . However, as it is known that cell-cycle progression in general (Pegg, 1986) , including that induced by c-Myc, is dependent on the activity of the Myc target gene, ODC, the observation that the cells do not continue to express ODC is a good reason for why this can occur. The continued expression of c-Myc in U937d7 cells without accompanying cell-cycle progression caused us to consider whether the block to dierentiation of these cells was invoked by the Myc protein in a cellcycle, and also ODC, independent manner. When we down-regulated the levels of c-Myc protein in U937d7 cells with an antisense oligonucleotide, we did ®nd that the cells acquired a terminally dierentiated phenotype.
While this is the ®rst observation that c-Myc can block dierentiation by a mechanism dissociated from its eects on cell-cycle progression, it is not the ®rst time that the phenotypic eects of c-Myc have been shown to arise through divergent mechanisms. La Rocca et al. (1994) examined the eects of a series of C-terminal truncations of the c-Myc protein for their ability to transform and/or block the dierentiation of primary quail myoblasts. One of these mutants retained the capacity to transform these cells, but had no eect upon the ability of the cells to dierentiate. However, as it is not known how the processes of cell cycle progression in human myeloid cells relates to morphological transformation in quail myoblasts, it is impossible to predict how these ®ndings might be related.
The only previous study which would indicate that c-Myc regulates the processes of cell ± cycle progression and dierentiation in myeloid cells by two dierent mechanisms has been presented by Luk et al. (1982) . They reported that the treatment of human leukaemic HL60 cells with the ODC inhibitor, DFMO, caused a withdrawal from the cell cycle, but did not aect the dierentiation status of these cells. It has, however, been shown that the down-regulation of the levels of c-Myc in HL60 cells by antisense oligonucleotides results in their dierentiation (Holt et al., 1988; Bacon and Wickstrom, 1991) . Together, these two ®ndings indicate that c-Myc regulates this differentiation process via a mechanism which is not dependent on the activity of ODC.
If the block to dierentiation of myeloid cells is neither cell cycle nor ODC-dependent, how then might it be considered that c-Myc can bring about this phenotypic eect? A simple explanation is that c-Myc works solely in conjunction with Max to regulate the expression of its target genes through the E-box motif, CACGTG. The way in which it independently regulates the processes of cell-cycle progression and dierentiation is explained by having two sub-sets of Myc target genes. One set of genes regulates cell-cycle progression and will therefore contain ODC and the other set, which we have shown here to exclude ODC, regulates dierentiation.
An alternative more complicated model to explain cMyc's eects on dierentiation is represented in Figure  8 . In this case, as it has been shown that the ability of c-Myc to aect cell-cycle progression is dependent not only on the activity of ODC, but also on dimerization with Max (Amati et al., 1993b) , the pathway to cellcycle progression remains the same as in the simple scheme. However, since there is no evidence that c-Myc requires dimerization with Max in order to block dierentiation, it is possible that Myc forms a complex with a dierent protein to regulate a sub-set of genes, X. In this respect, it is pertinent that, while c-Myc has been shown to block the dierentiation of the nerve growth factor-responsive PC12 cell line (Maruyama et al., 1987) , it has recently been reported that these cells are devoid of functional Max protein (Hopewell and Zi, 1995) . A number of other proteins have now been shown to interact with c-Myc, e.g. the transcription factors YY-1 (Shrivastava et al., 1993) and TFII-I (Roy et al., 1993) , and the Rb-related protein, p107 (Beijersbergen et al., 1994; Gu et al., 1994) . However, the way in which any of these might aect the ability of c-Myc to inhibit the dierentiation process is yet to be determined.
The model in Figure 8 is further complicated by the consideration that the regulation of the dierentiationblocking genes X may not occur via c-Myc binding to the E-box motif, CACGTG, since the larger translation product of c-myc can, in conjunction with Max, activate transcription through the binding sites of the C/EBP family of transcription factors (Hann et al., 1994) . Alternatively, it has been shown that c-Myc can repress transcription through the Initiator element (Inr) by a Max-independent mechanism (Roy et al., 1993).
Two genes which are thought to be regulated in this way are cyclin D1 and C/EBPa (Phillip et al., 1994; Li et al., 1994) . With respect to the control of dierentiation, the repression of C/EBPa is particularly interesting. It has been shown that enforced expression of c-Myc in the pre-adipocyte cell line 3T3-L1 leads not only to C/EBPa repression (Li et al., 1994) , but also inhibits the ability of the cells to dierentiate terminally. Moreover, the enforced expression of C/EBPa in these cells has been shown to be sucient to overcome the dierentiation blockage induced by c-Myc, possibly indicating that it is directly through the repression of C/EBPa that c-Myc negatively regulates this process (Freytag and Geddes, 1992) .
Although both these models can be supported by evidence from previous reports, none of those studies relate directly to the eects of c-Myc on dierentiation per se. Therefore, our ®ndings indicate that more work is now required to elucidate the role these Myc-binding factors have in the mechanism by which c-Myc controls dierentiation in both myeloid and other cell types.
Materials and methods
Culture of U937 cells
U937d+ cells were obtained from the European Collection of Animal Cell Cultures, Porton Down, UK. U937d7 cells arose spontaneously from cultures of`wild-type' U937 cells and are held within stocks at the Beatson Institute. In order to con®rm that U937d7 cells were derived from U937d+ cells, and that the U937d7 cells did not merely represent contamination with a dierent cell line which does not dierentiate, DNAs from U937d+ and U937d7 cells were analysed by DNA ®ngerprinting (Stacey et al., 1992) with a Jeries' multi-locus probe (33.15), using a kit from Cellmark Diagnostics (Abingdon, Oxon). They were found to be identical by this criterion.
Both U937 cell lines were grown in suspension culture in RPMI 1640 medium (Biological Industries, Israel), supplemented with 10% foetal calf serum (Gibco BRL), 1 mM sodium pyruvate (Gibco BRL) and 2 mM glutamine (Gibco BRL) in an atmosphere of 5% CO 2 in air at 378C. Cultures were passaged every 48 h and were seeded at a density of 5610 5 cells/ml. Dierentiation and/or growth arrest was induced by addition of 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (Sigma) directly to the tissue culture medium to a ®nal concentration of 1.6610
The proportion of cells terminally dierentiated was assayed by determining non-speci®c esterase (NSE) activity using the diagnostic kit 91-A from Sigma as recommended by the supplier. Two slides were prepared for each time point and 100 cells on each were scored.
Treatment with oligonucleotides
Nuclease-protected phosphorothioate oligonucleotides were synthesised at the Beatson Institute using standard phosphoramidite chemistry. They were added daily to the tissue culture medium, for a period of 5 days at a ®nal concentration of 20 mM. The c-myc antisense oligonucleotide (AACGTTGAGGGGCAT) was targeted against the 5' end of the mRNA and has been described previously (Wickstrom et al., 1988; Bacon and Wickstrom, 1991) . The other three oligonucleotides used in this study were: (a), the complementary c-myc sense oligonucleotide (ATGCCCCTCAACGTT) and (b), random/degenerate oligonucleotides of the same length as the c-myc antisense oligonucleotide (1: ACTGACTGACTGACT; 2: ACT-GACTGGGGACTG).
Flow cytometry
At the indicated times post-treatment, both adherent and suspension cells were harvested and washed twice in icecold PBS. The cells were then ®xed by resuspension in 70% ethanol to give a ®nal concentration of approximately 10 6 / ml and stored at 48C until required. To assess the cell-cycle status of each population of cells, stored samples were centrifuged and resuspended once again to a concentration of 10 6 /ml in 15 mM MgCl 2 , 0.002% (w/v) Chromomycin A3 (Sigma). After incubation in this stain at room temperature for 30 min in the dark, these samples were analysed using a Fluorescence Activated Cell Sorter (FACstar, Becton Dickinson). Equal numbers of events were analysed for each population of cells and cell-cycle related DNA pro®les and their analyses were undertaken using the Consort system (Becton Dickinson).
Western blot analysis
Samples of cells from the various time points indicated were harvested by centrifugation or scraped from the tissue culture dish and subsequently washed twice in ice cold PBS. They were then lysed in SDS ± PAGE sample buer (16 sample buer is 20% (v/v) glycerol, 2% (w/v) SDS, 100 mM tris pH 6.8 and to which 5% b-mercaptoethanol is added immediately prior to lysing the cells) and boiled for 5 min prior to being chilled on ice. Lysates were then sonicated in order to shear high molecular weight DNA and then centrifuged at 14 000 rev/min for 2 min at 48C in a microfuge. The resultant supernatants were aliquotted and stored at 7708C until required. Figure 8 A model for the regulation of myeloid dierentiation by a Max-independent mechanism is depicted. In this situation, while Myc aects cell-cycle progression via dimerization with Max, its eect on dierentiation is shown to possibly arise through interaction with a second, and as yet unknown factor(?). Furthermore, this scheme also includes the possibility that c-Myc regulates its dierentiation-blocking genes(X), either in conjunction with Max or ?, via a DNA-binding site that is distinct from the previously described E-box motif (CACGTG) Equal quantities of protein (measured using the Bradford assay) from each time point were separated by electrophoresis at 30 mA for 16 h through 7% SDS-polyacrylamide gels (30% acrylamide stock solution: 29% [w/v] acrylamide, 0.4% [w/v] bisacrylamide). The proteins from these gels were then transferred to Transblot nitro-cellulose membrane (Biorad) by semi-dry electro-blotting at 180 mA for 1 h. Detection of c-Myc protein on these blots was done with an antibody raised against human c-Myc, which was a kind gift of Dr D Gillespie of the Beatson Institute and which has been described previously (Crouch et al., 1993; La Rocca et al., 1994) . Blots were ®rst blocked for 16 h in PBS containing 5% (w/v) non-fat milk powder, 0.05% Tween 20 (Sigma), and then incubated in this solution with the c-Myc antiserum for 1 h, then with an anti-rabbit horseradish peroxidaseconjugated secondary antibody (Promega) for 1 h. The extent of reactivity against c-Myc was then ascertained by using the ECL Western blotting system (Amersham) and exposure to Kodak X-OMAT ®lm.
Northern blot analysis
Total cellular RNA was isolated using RNAzol B (Biogenesis, England), with the preparation being undertaken as advised by the manufacturers. RNA was denatured by suspension in 50% formamide, 2.2 M formaldehyde in 40 mM 3-(N-morpholino)propane sulphonic acid, 10 mM sodium acetate, 1 mM EDTA, pH 7.0 and heating at 658C for 15 min. 15 mg of RNA per lane was size-fractionated by elecrophoresis through 1.25% agarose gels containing 2.2 M formaldehyde. Gels were washed in distilled water (2630 min) followed by transfer to Hybond N + membranes (Amersham) by capillary blotting using 206SSC (16SSC is 0.15 M NaCl, 0.015 M sodium citrate, pH 7).
Preparation of hybridisation probes
The ODC probe used was a full length cDNA clone of the human ODC gene and has been described previously (Hickok et al., 1990) . The max probe was a 500 bp fragment of the plasmid pSTMax7 (a kind gift of Drs DH Crouch and DAF Gillespie of the Beatson Institute) containing the entire coding region of the human max gene. The mxi1 probe was generated from uninduced HL60
RNA by RT ± PCR using the primers: 5'-GGAGCGAA-GAGTGTGAACAT-3' (forward); 5'-TACTCAATGTAG-TATGAG-3' (reverse), which results in the ampli®cation of the entire coding region of the mRNA. The mad1 probe was a 1 kb fragment of the plasmid pVZMad (a kind gift provided by Dr D Ayer, Fred Hutchinson Cancer Research Center, Seattle, USA) containing the entire coding region of the human mad1 mRNA. The b 2 -microglobulin probe comprises 97% of the coding region plus 3' untranslated sequence of the human cDNA which was previously cloned into the PstI site of pBR322 (Suggs et al., 1981) . All probes were radio-labelled with [ 32 P]dCTP by random priming using a kit supplied by Boehringer Mannheim.
Hybridisation
Nylon membranes were pre-hybridised in a solution of 50% formamide, 56SSPE (16SSPE is 0.18 M NaCl, 0.01 M sodium phosphate pH 7.4, 0.1 mM Na 2 EDTA), 56 Denhardt's reagent, 0.5% (w/v) SDS and 200 mg/ml sonicated salmon sperm DNA at 428C for 4 h. Radiolabelled probe was then added to this solution at a ®nal concentration of 1610 6 c.p.m./ml and the incubation continued for a further 16 to 24 h. The blots were then washed (2620 min in 26SSC, 0.1% SDS at room temperature; then 45 min in 0.16SSC, 0.1% SDS at 658C), and exposed to Kodak X-OMAT ®lm with intensifying screens at 7708C. Autoradiographs were quanti®ed by scanning laser densitometry using apparatus from Molecular Dynamics and software from PDI.
